Calton & Associates’s Medicines Co MDCO Stock Holding History

Calton & Associates’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,651	Closed	-$233K	–	399
2019 Q3	$233K	Buy	+4,651	New	+$186K	0.05%	286

Other funds holding MDCO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Calton & Associates's MDCO Position: Q4 2019 in Review

Calton & Associates sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 4,651 shares — an estimated $233K sold.

Calton & Associates first reported a position in MDCO in Q3 2019 and held it in 1 quarter. The position peaked at $233K in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

Calton & Associates reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
Calton & Associates sold 4,651 Medicines Co shares in Q4 2019, an estimated $233K.
Calton & Associates first reported a position in Medicines Co in Q3 2019 and held it in 1 quarter.
Calton & Associates's Medicines Co position peaked at $233K in Q3 2019.
284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Calton & Associates's 13F filing for Q4 2019, filed 3 Feb 2020.